Moderna announces clinical update on bivalent covid-19 booster platform

Moderna's first bivalent booster vaccine candidate, mrna-1273.211, demonstrated superior neutralizing titers compared to mrna-1273 against all variants of concern, including omicron; superiority was maintained for six months after booster for the beta and omicron variants tolerability and safety of the bivalent booster were consistent with authorized 50 Μg mrna-1273 booster moderna is evaluating an updated bivalent booster incorporating more omicron-specific mutations (mrna-1273.214) in a phase 2/3 clinical study; initial data on this candidate, expected in the second quarter, will inform selection of fall 2022 booster for northern hemisphere cambridge, ma / accesswire / april 19, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines today announced new clinical data on its bivalent covid-19 booster platform including data on the company's first bivalent booster candidate, mrna-1273.211, which includes mutations found in the beta variant of concern, several of which have been persistent in more recent variants of concern including omicron. a 50 Μg booster dose of mrna-1273.211 demonstrated superiority against beta, delta and omicron variants of concern one month after administration.
MRNA Ratings Summary
MRNA Quant Ranking